Revenue: EUR429 million for H1 2024, 15.5% growth year-on-year.Organic Growth at CER: 12.8% overall, with North America at 26.2%.EBITDA Margin: Increased by 30
Aug 01, 2024 / 07:30AM GMTOperator Good morning, and welcome to Fagron's H1 2024 results conference call, hosted by Rafael Padilla, CEO; and Karin de Jong, CFO.
Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 23 augustus 2024 – 18u CET Voortgang aandeleninkoopprogramma Fagron In de periode...
Regulated informationNazareth /Rotterdam , 13 May 2024 – 7PM CET Fagron shareholders approve all voting items at AGM and EGM Fagron, the leading global player in pharmaceutical compounding, held...
/PRNewswire/ -- The gene panel market size is expected to grow by USD 3.23 million from 2022 to 2027. In addition, the momentum of the market will be...
/PRNewswire/ -- The compounding pharmacy market size is estimated to grow by USD 1,682.04 million from 2022 to 2027. The market is estimated to accelerate at a...
The Global Alopecia Market Size was valued at USD 7.1 billion in 2021 and the worldwide alopecia market size is expected to reach USD 13.7 billion by 2030,...
/PRNewswire/ -- Allied Market Research published a report, titled, "Compounding Pharmacies Market by Therapeutic Area (Pain Management, Hormone Replacement...
26 May 2021 Alychlo NV announces today its intention to sell approximately 3.6 million existing ordinary shares in Fagron NV to institutional investors by means of a private placement via an...